Recommendations Issued for Endoscopic Eradication Therapy in Barrett Esophagus
By Elana Gotkine HealthDay Reporter
THURSDAY, May 23, 2024 -- In a clinical practice guideline issued by the American Gastroenterological Association and published online in the June issue of Gastroenterology, updated evidence-based recommendations are presented for the use of endoscopic eradication therapy (EET) in patients with Barrett esophagus (BE) and related neoplasia.
Joel H. Rubenstein, M.D., from the Lieutenant Colonel Charles S. Kettles Veterans Affairs Medical Center in Ann Arbor, Michigan, and colleagues agreed on five recommendations for EET use in BE and related neoplasia. The panel made a strong recommendation for EET in patients with BE high-grade dysplasia and a conditional recommendation against EET in BE without dysplasia based on the available evidence.
In addition, the authors made a conditional recommendation in favor of EET in BE low-grade dysplasia and noted that surveillance endoscopy could reasonably be selected for patients with BE low-grade dysplasia who place a higher value on the potential harms and lower value on the uncertain benefits regarding reduction of esophageal cancer mortality. A conditional recommendation was made in favor of focal endoscopic mucosal resection (EMR) plus ablation over stepwise EMR in patients with visible lesions. The use of either EMR or endoscopic submucosal dissection was suggested based on lesion characteristics for patients with visible neoplastic lesions undergoing resection.
"While the benefit is clear for patients with high-grade dysplasia, we suggest considering endoscopic eradication therapy for patients with low-grade dysplasia after clearly discussing the risks and benefits of endoscopic therapy," coauthor Tarek Sawas, M.D., from the University of Texas Southwestern in Dallas, said in a statement.
Several authors disclosed ties to the biopharmaceutical and medical device industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
Lower Rates of Symptom Rebound Seen After H. Pylori Eradication in GERD
THURSDAY, March 6, 2025 -- For patients with gastroesophageal reflux disease (GERD), those with Helicobacter pylori infection have significantly lower rates of symptom rebound and...
Transcutaneous Electrical Stimulation Aids Gastroesophageal Reflux Disease
TUESDAY, Feb. 4, 2025 -- A transcutaneous electrical stimulation system (TESS) is effective in reducing both symptoms and esophageal acid exposure time in patients with...
Endoscopic Full-Thickness Plication Efficacious for GERD
FRIDAY, Dec. 6, 2024 -- Endoscopic full-thickness plication (EFTP), which improves the valvular mechanism of the gastroesophageal junction, is efficacious for managing...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.